Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme

NCT00423735 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00423735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00423735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 24, 2007
Completion date
September 4, 2018
Enrollment
64 (actual)
Sites
188

Conditions

As the registry lists them; a condition with its own page is linked.

adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm